Associated Faculty

Jeffrey Sawyer, Ph.D.

Professor of Pathology, UAMS
Director of Cytogenetics

Ph.D. Florida Institute of Technology, Melbourne, Florida
Director, Cytogenetics Laboratory, Clinical and Diagnostic Foundation, Driscoll Foundation Children's Hospital, Corpus Christi, Texas

Selected Publications:

Sawyer JR, Tricot G, Lukacs JL, Lichti-Binz R, Tain E, Barlogie B, Shaughnessy J.  Genomic Instability in Multiple Myeloma: Evidence for Jumping Segmental Duplications of Chromosome 1q.  Genes Chromosomes and Cancer,  42:95-106,       2005.

Hanamura I, Stewart JP, Huang U, Zhan F, Santra M, Sawyer JR, Hollmig K, Zangarri M, Pineda-Roman M, van Rhee F, Cavall F, Burington B, Crowley J, Tricot G, Barlogie B, Shaughnessy Jr. JD.  Frequent gain of chromosome band 1q21 in plasma cell dyscrasias detected by fluorescence in situ hybridization: Incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem cell transplantations.  Blood 108:1724-1732, 2006.

Zhan F, Huang Y, Colla S, Stewart JP, Hanamura I, Gupta S, Epstein J, Yaccoby S, Sawyer J, Burington B, Hollimig K, Pineda-Roman M, Tricot G, van Rhee F, Walker R, Zangari M, Crowley J, Barlogie B, Shaughnessy Jr. JD.  The molecular classification of multiple myeloma.  Blood, 108:2020-2028, 2006.

Shaughnessy, Jr, J, Zhan F, Burington B, Huang Y, Colla S, Hanamura I,  Stewart J, Kordsmeier B, Randolph C, Williams D, Xiao Y, Xu H, Epstein j, Anaissie E,  Krishna S, Cottler-Fox M, Hollmig K, Mohiuddin A, Pineda-Roman M, Tricot G,  van Rhee F, Sawyer J, Alsayed Y, Walker R, Zangari M, Crowley J, Barlogie B. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1.
Blood , 109:2276-2284, 2007

Barlogie B, Tricot G, Haessler J, van Rhee R, Cottler-Fox M, Annaisse E, Waldron J, Pineda-Roman M, thertulien R, Zangari M, hollmig K, Mohiuddin A, Alsyaed Y, hoering A, Crowley J, Sawyer J.  Cytogenetically defined myelodysplasia after melphalan-based autotranplants for multiple myeloma linked to poor hematopoietic stem-cell mobilization: the Arkansas experience in more than 3000 patients treated since 1989. Blood. 111:94-100, 2008.

Having problems with the site? E-mail the Webmaster.
Copyright 2002-2005, Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences
Terms and Conditions of Use

The information on the Myeloma Institute web site is not intended as a substitute for professional medical attention. The information is intended only as an aid in understanding current medical knowledge. A physician should always be consulted for any health concern or medical condition. The Myeloma Institute web site provides links to other organizations as a service to our readers. The Myeloma Institute is not responsible for the information provided on other web sites.